{"organizations": [], "uuid": "8b51d79a1dbd782301fad6e2a83909c6790b226d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180226.html", "section_title": "Archive News &amp; Video for Monday, 26 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-luye-pharma-group-says-cfda-accept/brief-luye-pharma-group-says-cfda-accepted-clinical-trial-application-for-cos-anti-tumor-drug-idUSFWN1QG0J2", "country": "US", "domain_rank": 408, "title": "BRIEF-Luye Pharma Group Says ‍CFDA Accepted Clinical Trial Application For Co's Anti-Tumor Drug", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.376, "site_type": "news", "published": "2018-02-26T17:52:00.000+02:00", "replies_count": 0, "uuid": "8b51d79a1dbd782301fad6e2a83909c6790b226d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-luye-pharma-group-says-cfda-accept/brief-luye-pharma-group-says-cfda-accepted-clinical-trial-application-for-cos-anti-tumor-drug-idUSFWN1QG0J2", "ord_in_thread": 0, "title": "BRIEF-Luye Pharma Group Says ‍CFDA Accepted Clinical Trial Application For Co's Anti-Tumor Drug", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "anti-tumor drug feb", "sentiment": "negative"}, {"name": "cfda", "sentiment": "negative"}, {"name": "reuters) - luye pharma group ltd", "sentiment": "neutral"}, {"name": "brief-luye pharma group says ‍cfda accepted clinical trial application for co", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 26 (Reuters) - Luye Pharma Group Ltd:\n* ‍CFDA OFFICIALLY ACCEPTED CLINICAL TRIAL APPLICATION FOR ANTI-TUMOR DRUG Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-26T17:52:00.000+02:00", "crawled": "2018-02-27T14:54:31.010+02:00", "highlightTitle": ""}